This fund aims to replicate the investment performance of U.S.-listed companies, including equity shares and depositary receipts, that are primarily engaged in two sectors: either researching, developing, and bringing to market treatments or vaccines for infectious diseases, or producing, researching, and supplying biological diagnostic tests for patients. At least 80% of the fund's total assets will be invested in the specific securities that constitute its underlying index. It is important to note that this fund is structured as non-diversified.